Richard J. Daly serves as the President and CEO of Catalyst Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. With a strong background in the pharmaceutical industry, Daly has been instrumental in guiding Catalyst Pharmaceuticals through significant growth and development. Before joining Catalyst Pharmaceuticals, Daly held various leadership positions in the healthcare sector. He previously served as the President and Chief Executive Officer of Crealta Pharmaceuticals, where he led the company through a successful acquisition by Horizon Pharma. Prior to Crealta, Daly was the President and CEO of Auxilium Pharmaceuticals, where he oversaw the company's growth and eventual acquisition by Endo International. His extensive experience in strategic planning, business development, and operational management has been crucial in driving Catalyst Pharmaceuticals forward. Under Daly's leadership, Catalyst Pharmaceuticals has achieved several milestones, including the successful launch and commercialization of Firdapse, a treatment for Lambert-Eaton myasthenic syndrome (LEMS). Daly's strategic vision and commitment to patient care have positioned the company as a leader in the rare disease space. His role involves overseeing the company's overall operations, setting strategic goals, and ensuring that Catalyst Pharmaceuticals continues to innovate and deliver life-changing therapies to patients in need.